<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by Roman Molla on Medium]]></title>
        <description><![CDATA[Stories by Roman Molla on Medium]]></description>
        <link>https://medium.com/@romanmolla?source=rss-544e783b9f48------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/1*6_jMrJ_iM_FScn__QCjzpQ.jpeg</url>
            <title>Stories by Roman Molla on Medium</title>
            <link>https://medium.com/@romanmolla?source=rss-544e783b9f48------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Tue, 17 Nov 2026 14:14:12 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@romanmolla/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[I counted every registered clinical trial for 20 peptides]]></title>
            <link>https://medium.com/@romanmolla/i-counted-every-registered-clinical-trial-for-20-peptides-9d56a8a42185?source=rss-544e783b9f48------2</link>
            <guid isPermaLink="false">https://medium.com/p/9d56a8a42185</guid>
            <category><![CDATA[semaglutide]]></category>
            <category><![CDATA[clinical-trials]]></category>
            <category><![CDATA[research-peptide]]></category>
            <category><![CDATA[peptides]]></category>
            <category><![CDATA[bpc-157]]></category>
            <dc:creator><![CDATA[Roman Molla]]></dc:creator>
            <pubDate>Mon, 21 Sep 2026 18:05:31 GMT</pubDate>
            <atom:updated>2026-09-21T18:05:31.806Z</atom:updated>
            <content:encoded><![CDATA[<h4>Semaglutide has 538. BPC-157 has 3. Six of them have none.</h4><p>People ask me the same question every week, in slightly different words. How much real human research is there on this compound?</p><p>I never had a good answer. I had a pile of review papers, each about one peptide, each written by someone who cared a lot about that peptide. What I wanted was one table, built the same way for every compound, that I could hand to someone and say: check it yourself.</p><p>So I built it.</p><p>Disclosure before I go further. I run <a href="https://curo.you/?utm_source=medium&amp;utm_medium=article&amp;utm_campaign=peptide-trial-count">Curo</a>, which supplies research compounds to labs. I have a commercial interest in this field, and you should read everything below knowing that. It is also the reason I wanted the honest number and not the flattering one.</p><h4>What I did</h4><p>ClinicalTrials.gov is the largest public trial registry in the world. US law has required most drug trials to register there since 2007, and the registry has a free public API. That makes it countable, which most things in this industry are not.</p><p>I picked 20 compounds. They are the ones sold most often as research materials, plus the approved drugs from the same families. For each one I searched the intervention field for the name and every code name and brand name I could find. BPC-157 alone goes by BPC 157, Bepecin and PL 14736.</p><p>Then three rules. Interventional studies only. The compound has to be named in the study’s own intervention list, because a search hit is not enough. And each registry number counts once.</p><p>I ran it on September 21, 2026.</p><h4>The number</h4><p>896 unique trials across the 20 compounds.</p><p>That sounds like a lot until you see how it splits.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*VnX3ED_fu4rUf_eSoHcwow.png" /></figure><p>Semaglutide is named in 538 of them. That is 60 percent of everything I counted, for one compound. Tirzepatide has 210. Add cagrilintide at 44 and retatrutide at 33, and the four metabolic compounds cover 768 of the 896 trials. (Some trials test two of them together, so the four numbers add up to more than 768.)</p><p>The other 16 compounds share 129.</p><p>Here is the part that stuck with me. Semaglutide has 237 trials recruiting or active right now. That is more than the lifetime total of the other 18 compounds put together.</p><h4>Three tiers</h4><p>Once the table was done, it sorted itself.</p><p>Hundreds: semaglutide and tirzepatide. Approved drugs with large sponsors behind them. Of the 271 Phase 3 entries I counted, all but 20 belong to the four metabolic compounds.</p><p>Dozens: compounds that have had a real development program at some point. Thymosin alpha 1 leads this group with 55. Tesamorelin has 20. Thymosin beta 4, which the research market calls TB-500, has 18, from its years as an eye and wound candidate. NAD+ has 18. Bremelanotide, or PT-141, has 10.</p><p>A handful or none: BPC-157 has 3. Ipamorelin has 2, both Phase 2, both finished more than a decade ago. GHK-Cu, MOTS-c and CJC-1295 have 1 each. The CJC-1295 trial was terminated. The GHK-Cu and MOTS-c entries are both from 2026, which means that until this year each had zero.</p><p>And six compounds have no entry: AOD-9604, Selank, Semax, Epithalon, KPV and Pinealon.</p><p>I put the <a href="https://curo.you/insights/peptide-clinical-trials-registry-count-2026?utm_source=medium&amp;utm_medium=article&amp;utm_campaign=peptide-trial-count">full table on curo.you</a>, with Phase 3 counts, completed counts, and the first trial year for each compound.</p><h4>BPC-157 has three trials.</h4><p>This is the one that surprises people, because BPC-157 is probably the most talked-about research peptide on the internet.</p><p>The three entries are a 2015 Phase 1 study whose status is now listed as unknown, a Phase 1 study that has not started recruiting, and a Phase 2 study that is recruiting. None is Phase 3. None is marked completed.</p><p>You will see the number 4 in other places, including on one of my own pages. A raw search does return 4. The fourth is a gummy product that does not name BPC-157 as its intervention, so under my rules it is out. I would sooner explain a smaller number than defend a bigger one.</p><p>None of this says BPC-157 is good or bad. It says the published record is mostly cell culture and rodents, and I wrote up <a href="https://curo.you/insights/bpc-157-what-the-research-record-shows?utm_source=medium&amp;utm_medium=article&amp;utm_campaign=peptide-trial-count">what that record shows</a> separately.</p><h4>A zero is not what it looks like</h4><p>I almost left the zeros out, because they are easy to misread.</p><p>Zero registered trials is a fact about one US database. Semax and Selank were developed in Russia, and their human studies were run and published there. Epithalon and Pinealon come from the same St. Petersburg research tradition. AOD-9604 went through human trials in Australia in the 2000s, outside this registry. KPV has a laboratory and animal literature.</p><p>So the zero does not mean nobody studied it. It means nobody is running registered, prospective human work on it in the system the US uses. Those are different statements, and people mix them up in both directions.</p><p>If you want one compound’s history in detail, the <a href="https://curo.you/insights/semax-acth-fragment-fda-2026-review?utm_source=medium&amp;utm_medium=article&amp;utm_campaign=peptide-trial-count">Semax write-up</a> is a good example of how much exists outside the registry.</p><h4>Why the strict rule matters</h4><p>The rule about the intervention list changed the results more than I expected.</p><p>A raw search for NAD+ returns 264 studies. Most of them test nicotinamide riboside or another precursor. Only 18 name NAD+ itself.</p><p>A raw search for MOTS-c returns 5. Four of those only measure the peptide in blood. Only one actually administers it.</p><p>If you have ever seen a big trial number quoted for a small compound, this is usually how it happened. Someone typed the name into the search box and wrote down the first number.</p><p>## What I can’t tell you</p><p>Sponsors type intervention names by hand. An odd spelling can slip past me. The registry leans American. And registration only tells you a study was planned. It does not tell you the study finished, or published, or found anything.</p><p>Retatrutide is the clean example. It has 33 registered trials and, as of this month, no approval anywhere.</p><h4>What I took from it</h4><p>Two things.</p><p>First, the gap between the top of the table and the bottom is much wider than the way people talk about these compounds. Online, they all get discussed in the same tone. In the registry, one of them has 538 trials and another has 1.</p><p>Second, when a compound has three trials, the material itself matters more. A lab working with semaglutide has a mountain of published human data to compare against. A lab working with BPC-157 has almost none. The identity and purity of what is in front of them carries most of the weight. That is why every lot we ship has its own certificate of analysis, and why I wrote a guide on <a href="https://curo.you/help/quality-verification/certificates-of-analysis-how-to-verify-your-lot?utm_source=medium&amp;utm_medium=article&amp;utm_campaign=peptide-trial-count">how to verify a lot against its COA</a> that works for any supplier’s paperwork, not only ours.</p><h4>Check my count</h4><p>The method is four rules and the API is free. <a href="https://curo.you/insights/peptide-clinical-trials-registry-count-2026?utm_source=medium&amp;utm_medium=article&amp;utm_campaign=peptide-trial-count">The full table, the method and the trial links are on curo.you</a> if you want to rerun it or tell me what I missed. I plan to rerun it every quarter, and I expect the bottom of the table to move before the top does.</p><p>You can quote any figure here. Please credit ClinicalTrials.gov as the source underneath.</p><p>I run <a href="https://curo.you/product-catalog?utm_source=medium&amp;utm_medium=article&amp;utm_campaign=peptide-trial-count">Curo</a>. I write about peptide research, testing standards, and the regulation around them.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=9d56a8a42185" width="1" height="1" alt="">]]></content:encoded>
        </item>
    </channel>
</rss>